Next fdcyd_THU NSC112907 (CT029-402-448-003), to#3 milestone 2 - THU bulk drug analysis, DTP-18-026, HHSN261201700014I, analysis of anti-cancer chemical & pharmaceutical formulations PRB

Ended Awarded Sep 7, 2018 Last action Sep 6, 2018

Contract number: 75N91018F00003
Awardee: Sri International UEI SRG2J1WS9X63
Awarding agency: National Cancer Institute National Institutes of Health, Department of Health and Human Services
Obligated: $23,454

Award facts

Opportunity: N02CM7700416 Solicitation number

Analysis of Anti-Cancer Chemicals & Pharmaceutical Formulations Award Notice · Posted Feb 22, 2017

Analysis of Bulk Drugs & Pharmaceutical Formulations Award Notice · Posted Dec 9, 2016
Contract value 100% obligated: $23,454.00 Current and potential, with all options
Completion date 100% complete: Dec 9, 2018 Current and potential, with all options
NAICS code: 325412 Pharmaceutical Preparation Manufacturing
PSC: B504 Special Studies/Analysis- Chemical/Biological
Set-aside: No set-aside
Competition: Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing: Cost Plus Fixed Fee
Place of performance: Menlo Park, CA 94025, USA
Legislative mandates: Service Contract Inventory FAR subpart 4.17

Award details come from SAM.gov/FPDS.

75N91018F00003 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on September 7, 2018.

The government has obligated $23,454 on 75N91018F00003.

Yes. 75N91018F00003 is a delivery order under HHSN261201700014I, an indefinite delivery contract, on NIH Analysis of Anti-Cancer Chemicals 2017-2022.

The extent of competition for 75N91018F00003 was full and open competition. The government received 1 offer.

On GovTribe

Try for free Login